SPATA31A7: A Potential Drug Target and Biomarker (G26165)

Target Name: SPATA31A7

NCBI ID: G26165

SPATA31A7

SPATA31A7: A Potential Drug Target and Biomarker

SPATA31A7 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique sequence similarity to known transcription factors has led to its interest in the study of gene regulation and its role in various diseases. In this article, we will explore the biology of SPATA31A7, its potential drug target properties, and its potential as a biomarker for various diseases.

The discovery and characterization of SPATA31A7

SPATA31A7 was first identified as a non-coding RNA molecule using RNA sequencing data. Its unique sequence similarity to known transcription factors, such as AP1 and MXI2, led to its study as a potential transcription factor. Further analysis of its sequence revealed that SPATA31A7 had 199 non-coding exons, and its protein product had 765 amino acid residues.

SPATA31A7 is a member of the POU gene family, which is known for the regulation of gene expression and involved in various cellular processes, including cell growth, differentiation, and DNA replication. The POU gene family has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, the study of SPATA31A7 as a potential drug target and biomarker is of high interest.

The potential drug target properties of SPATA31A7

SPATA31A7 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and DNA replication. Its expression has been shown to be regulated by various factors, including Wnt, TGF-β, and p53. Wnt and TGF-β are known for their role in cell growth and differentiation, while p53 is a well-known tumor suppressor gene that plays a crucial role in regulating cell apoptosis.

SPATA31A7 has also been shown to be involved in the regulation of DNA replication. Its expression has been shown to be regulated by factors such as Rb, which is a transcription factor that plays a role in the regulation of DNA replication. Rb is known for its role in the development and maintenance of cancer, and its inhibition has been shown to be effective in treating various types of cancer.

The potential biomarker properties of SPATA31A7

SPATA31A7 has been shown to have potential as a biomarker for various diseases. Its expression has been shown to be regulated by various factors, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, its study as a biomarker is of high interest.

SPATA31A7 has been shown to be involved in the regulation of cancer cell growth and apoptosis. Its expression has been shown to be regulated by factors such as Wnt, TGF-β, and p53, which are known for their role in cell growth and differentiation. Therefore, its expression levels may be used as a biomarker for cancer diagnosis and treatment.

SPATA31A7 has also been shown to be involved in the regulation of neurodegenerative diseases. Its expression has been shown to be regulated by factors such as Rb, which is a transcription factor that plays a role in the regulation of DNA replication. Rb is known for its role in the development and maintenance of neurodegenerative diseases, and its inhibition has been shown to be effective in treating various types of neurodegenerative diseases.

SPATA31A7 has also been shown to be involved in the regulation of developmental disorders. Its expression has

Protein Name: SPATA31 Subfamily A Member 7

Functions: May play a role in spermatogenesis

The "SPATA31A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPATA31A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets